Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from AbbVie

Stocks Settle Mostly Higher on President-Elect Trump’s Pro-Growth Promises

The S&P 500 Index ($SPX ) (SPY ) Monday closed up +0.10%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.69%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.05%. Stocks on Monday settled mixed, with the S&P 500 and the Dow Jones Industrials...

Is This Dividend King a Buy After a Strong Q3 Report?

Is This Dividend King a Buy After a Strong Q3 Report?

This might be the perfect opportunity to buy this growth and income stock at a discount.

Stocks Rally on Optimism in President-Elect Trump’s Policies

Stocks Rally on Optimism in President-Elect Trump’s Policies

The S&P 500 Index ($SPX ) (SPY ) today is up +0.28%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.94%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.07%. Stocks today are moderately higher, with the S&P 500 and the Dow Jones Industrials...

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

S&P 500 and Dow Jones Industrials at Record Highs as the Post-Election Rally Continues

The S&P 500 Index ($SPX ) (SPY ) today is up +0.21%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +1.02%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.19%. Stocks today are moderately higher, with the S&P 500 and the Dow Jones Industrials...

Are Wall Street Analysts Bullish on AbbVie Stock?

Despite AbbVie’s outperformance relative to the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook about the stock’s prospects.

Nasdaq Futures Climb on Upbeat Alphabet Results, U.S. GDP Data and More Big Tech Earnings on Tap

December Nasdaq 100 E-Mini futures (NQZ24) are trending up +0.28% this morning as strong quarterly results from Alphabet boosted sentiment, while investors also awaited a fresh batch of U.S. economic data and earnings reports from “Magnificent Seven” companies Microsoft and Meta.

HR leaders share how they're putting people first in an ever-changing workplace

HR professionals are navigating RTO, AI, cultural changes, and divisive virtual cultural issues.

inkl

Read news from The Economist, FT, and more,
with one subscription

3 Undervalued Dividend Aristocrats Poised for Explosive Gains in 2025

3 Undervalued Dividend Aristocrats Poised for Explosive Gains in 2025

Hunting for value? These three Dividend Aristocrats look cheap by today's valuations.

AbbVie's Q3 2024 Earnings: What to Expect

AbbVie's Q3 2024 Earnings: What to Expect

With AbbVie gearing up to release its third-quarter earnings later this month, analysts expect a marginal decline in earnings.

3 Highest-yielding Dividend Kings for Maximum Income and Stability

3 Highest-yielding Dividend Kings for Maximum Income and Stability

Looking for reliable yield? These three companies offer ever-increasing dividends and a lifetime of stability.

Pharma company funding for patient advocacy groups needs to be transparent

Pharma company funding for patient advocacy groups needs to be transparent

Patient groups should be playing a central role in Canada’s health-care system, advocating for their members by promoting the visibility of their conditions, pushing for more rapid and accurate diagnoses and lobbying for the introduction and funding of new treatments and drugs that may help relieve their members’ symptoms and…

The Conversation

3 Dividend Powerhouses, Including One With 7% Yield

3 Dividend Powerhouses, Including One With 7% Yield

By investing in these dividend powerhouses, investors can achieve reliable income, mitigate risk through diversification, and potentially enjoy capital gains.

Is AbbVie Stock Outperforming the Nasdaq?

Is AbbVie Stock Outperforming the Nasdaq?

AbbVie has recently outperformed the Nasdaq, and Wall Street analysts are moderately optimistic about the stock’s prospects.

3 Defensive Dividend Stocks to Scoop Up Now

3 Defensive Dividend Stocks to Scoop Up Now

Amid ongoing market uncertainty, Morgan Stanley believes these three defensive dividend-paying stocks could be ideal buys now.

Get all your
news in one place.

100's of premium titles.
One news app.

3 Safe High-Yield Dividend Stocks to Pounce on Now

In today's volatile market, dividend stocks remain one of the safest choices.

Nervous About the Market? 3 Defensive Stock Picks to Consider This August

Explore three defensive stock picks from the consumer staples, healthcare, and utilities sectors that offer stability amid market uncertainty in August.

Best Stocks to Buy for Fed Rate Cuts

The Federal Reserve cut rates again at its December meeting, and lower borrowing costs could boost these large-cap stocks.

What Are Wall Street Analysts' Target Price for Abbvie Stock?

Despite AbbVie stock’s robust price performance compared to the broader market over the past year, Wall Street analysts are moderately bullish about the stock’s prospects.

Get all your
news in one place.

100's of premium titles.
One news app.

Secure Decades of Passive Income: 3 Top Dividend Stocks to Buy Now

These companies have consistently paid and increased their dividends, and they have a growing earnings base to support their future payouts.

3 Highest-Yielding Dividend Kings That Wall Street Loves

A high yield doesn't necessarily translate to a buy. This article bridges the gap by combining high dividend payouts and buy ratings.

Option Volatility And Earnings Report For July 22 - 26

This week we have Tesla (TSLA), Microsoft (MSFT), Alphabet (GOOGL), Exxon Mobil (XOM), Visa (V), Abbvie (ABBV) and Chipotle Mexican Grill (CMG) all set to report.

AbbVie Earnings Preview: What to Expect

AbbVie is all set to announce its second-quarter results this month, and analysts forecast a double-digit decline in the company’s bottom-line figure.

Is Abbvie Stock Underperforming the S&P 500?

Despite headwinds from Humira patent expiry, potential price controls from the Inflation Reduction Act, and recent underperformance relative to the S&P 500, Wall Street analysts anticipate moderate gains in Abbvie stock.

Down 14% from All-Time Highs, is This Dividend King a Buy on the Dip?

With a strong product portfolio, this growth and income stock is an excellent long-term investment.

Abbvie Stock: Is Wall Street Bullish or Bearish?

Although Abbvie stock has been lagging behind the broader market over the past year, Wall Street analysts are still moderately bullish about its outlook.

1 … 4 5 6 7

People

185,346 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

the Federal Reserve

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

367,413 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play